Since their days as biomaterial specialists at New York University, founders of Orthogen, LLC have been exploring the frontiers of biomedical research. Originally a division of BioLok International, Orthogen went independent as a company in 2007, under the leadership of entrepreneur and scientist Dr. Harold Alexander. Alongside Dr. Sachin Mamidwar and their professional circle of medical consultants, they continue to develop exemplary nanotechnologies for regenerating bone.
By working closely with institutions like Rutgers University and New York University School of Dentistry, Orthogen harnesses over two decades of research in dental bone graft materials. Tradenamed NanoGen, their proprietary technology resulted in the development of first nanotechnology based dental bone graft. Because of the nanocrystalline structure of NanoGen, it undergoes controlled degradation over a period of 12-16 weeks and can be used as bone material during more traditional dental grafting. As NanoGen naturally degrades, it spurs the formation of calcium phosphate and bone regeneration. Within 3 to 4 months, grafting sites are filled in with regenerated vital bone.
In tandem with NanoGen, Orthogen's exploration of bone grafting expanded to DentoGen. Although in usage for 115 years, calcium sulfate was misperceived to be a mere defect filler. In their research, Orthogen conclusively demonstrated that calcium sulfate was more than highly biodegradable—it was also shown to stimulate bone growth, and proved non-toxic. Once implanted, the graft would dissolve into its constituent parts: calcium and sulfate ions. By the wonder of biochemistry, calcium and phosphate ions then bond into calcium phosphate.
To learn more about their latest research and innovations in dental bone grafting, one can visit their website at http://www.orthogencorp.com/.
SOURCE: Orthogen, LLC